Clarity Pharma (CU6) is held by 6 ASX ETFs. Over the last year it fell 60.1%: on $10,000, −$6007. We explain 9 big moves in that time.
About CU6
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$716.3m
- Held by6 ETFs
- Big moves9 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −5.9%peak −6.4%9 Oct 2026· Operational
Clarity Pharmaceuticals likely fell on profit-taking or disappointment after news of achieving its SECuRE cohort recruitment target failed to sustain the prior rally, with no new positive catalyst to drive further gains.
- +7.1%peak +15.5%5 Aug 2026· Sector Flow
CU6 rose sharply alongside a broader rally in Australian healthcare stocks, lifting the stock well above its normal daily range.
- −9.1%peak −10.3%7 Jul 2026· Unknown
Clarity Pharmaceuticals (CU6) fell sharply as investors sold into the stock after a near-15% rally the prior day, with no new positive catalysts to sustain the move and news articles specifically questioning the reasons behind the sell-off
- +19.0%peak +19.9%6 Jul 2026· Sector Flow
Clarity Pharmaceuticals rallied ~15% driven by renewed investor interest in the radiopharmaceutical sector, with market attention focusing on the company as a precision oncology developer amid a broader 'hot' radiopharma theme.
- +15.7%29 Jun 2026· Sector Flow
Clarity Pharmaceuticals' share price surged due to a broader sector flow into ASX biotech stocks, with the company set to present prostate cancer data at the EANM conference soon after.
- −11.0%26 Jun 2026· Stake Change
A substantial holder notice ceasing their holding in Clarity Pharmaceuticals triggered the stock decline, likely due to a major shareholder selling down their stake.
- +7.9%15 Apr 2026· Operational
Clarity Pharmaceuticals' share price rose 7.9% on April 15, 2026, likely recovering from a previous day's 5% drop following a manufacturing expansion announcement.
- +24.8%16 Feb 2026· Operational
Clarity Pharmaceuticals likely surged on a breakthrough moment in its radiopharmaceutical pipeline, as highlighted in subsequent news coverage.
- +15.1%16 Oct 2025· Contract
Clarity Pharmaceuticals announced a copper-67 supply agreement with Nusano, likely boosting investor confidence.
Held by 6 ETFs
Of every $10,000 in each fund, how much is in CU6 today.
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$240.24%
- ISOiShares S&P/ASX Small Ordinaries ETF$240.24%
- VSOVanguard MSCI Australian Small Companies Index ETF$110.11%
- VETHVanguard Ethically Conscious Australian Shares ETF$3.360.03%
- VASVanguard Australian Shares Index ETF$2.740.03%
- A300Global X Australia 300 ETF$2.410.02%
Why did CU6 rise 19.0% on 6 Jul 2026?
Clarity Pharma
Clarity Pharmaceuticals rallied ~15% driven by renewed investor interest in the radiopharmaceutical sector, with market attention focusing on the company as a precision oncology developer amid a broader 'hot' radiopharma theme.
There are no company-specific announcements to explain the move, so the catalyst appears to be thematic/sentiment-driven coverage from financial news outlets highlighting CU6 as a beneficiary of ongoing radiopharma sector momentum. The sector signal (AXHJ health index up only 0.83%) is well below the threshold needed to explain a 14.25% individual stock move, ruling out a broad sector lift as the primary driver. The volume ratio of 1.5x is elevated but not extreme, suggesting a news-driven sentiment burst rather than a major fundamental catalyst, and confidence is capped at medium because the news snippets are largely reactive commentary rather than evidence of a specific triggering event.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage
Sector / macro signals
What it did to the 6 ETFs holding CU6
On $10,000 in each fund, at the weight it holds today